Min Wu
Research Subjects
Research Interests
Min Wu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer E. Van Eyk
Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, USA
1 shared publication - Jonathan Braun
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
1 shared publication - Joseph E. Ebinger
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California
1 shared publication - Kimia Sobhani
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
1 shared publication - Magali Noval Rivas
Department of Pediatrics, Cedars-Sinai Guerin Children’s, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA
1 shared publication - Moshe Arditi
Department of Pediatrics, Cedars-Sinai Guerin Children’s (A.E.A., P.K.J., T.T.C., B.L.R., E.A.A., M.E.L., A.C.G., Y.L., S.C., T.R.C., M.A., M.N.R.), Cedars‑Sinai Health Sciences University, Los Angeles, CA
1 shared publication
Latest Publications
- Top Cited Papers
- 19 January 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (2)
BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers
BACKGROUND. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 1 million deaths worldwide; thus, there is an urgent need to develop preventive and therapeutic strategies. The antituberculosis vaccine bacillus Calmette-Guérin (BCG) demonstrates nonspecific, protective innate immune–boosting effects. Here, we determined whether a history of BCG vaccination was associated with decreased SARS-CoV-2 infection and seroconversion in a longitudinal, retrospective observational study of a diverse cohort of health care workers (HCWs). METHODS. We assessed SARS-CoV-2 seroprevalence and collected medical questionnaires, which included information on BCG vaccination status and preexisting demographic and clinical characteristics, from an observational cohort of HCWs in a multisite Los Angeles health care organization. We used multivariate analysis to determine whether a history of BCG vaccination was associated with decreased rates of SARS-CoV-2 infection and seroconversion. RESULTS. Of the 6201 HCWs, 29.6% reported a history of BCG vaccination, whereas 68.9% had not received BCG vaccination. Seroprevalence of anti–SARS-CoV-2 IgG as well as the incidence of self-reported clinical symptoms associated with coronavirus disease 2019 (COVID-19) were markedly decreased among HCWs with a history of BCG vaccination compared with those without BCG vaccination. After adjusting for age and sex, we found that a history of BCG vaccination, but not meningococcal, pneumococcal, or influenza vaccination, was associated with decreased SARS-CoV-2 IgG seroconversion. CONCLUSIONS. A history of BCG vaccination was associated with a decrease in the seroprevalence of anti–SARS-CoV-2 IgG and a lower number of participants who self-reported experiencing COVID-19–related clinical symptoms in this cohort of HCWs. Therefore, large randomized, prospective clinical trials of BCG vaccination are urgently needed to confirm whether BCG vaccination can confer a protective effect against SARS-CoV-2 infection.
- 19 January 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (2)
Top Cited PapersBCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers
BACKGROUND. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 1 million deaths worldwide; thus, there is an urgent need to develop preventive and therapeutic strategies. The antituberculosis vaccine bacillus Calmette-Guérin (BCG) demonstrates nonspecific, protective innate immune–boosting effects. Here, we determined whether a history of BCG vaccination was associated with decreased SARS-CoV-2 infection and seroconversion in a longitudinal, retrospective observational study of a diverse cohort of health care workers (HCWs). METHODS. We assessed SARS-CoV-2 seroprevalence and collected medical questionnaires, which included information on BCG vaccination status and preexisting demographic and clinical characteristics, from an observational cohort of HCWs in a multisite Los Angeles health care organization. We used multivariate analysis to determine whether a history of BCG vaccination was associated with decreased rates of SARS-CoV-2 infection and seroconversion. RESULTS. Of the 6201 HCWs, 29.6% reported a history of BCG vaccination, whereas 68.9% had not received BCG vaccination. Seroprevalence of anti–SARS-CoV-2 IgG as well as the incidence of self-reported clinical symptoms associated with coronavirus disease 2019 (COVID-19) were markedly decreased among HCWs with a history of BCG vaccination compared with those without BCG vaccination. After adjusting for age and sex, we found that a history of BCG vaccination, but not meningococcal, pneumococcal, or influenza vaccination, was associated with decreased SARS-CoV-2 IgG seroconversion. CONCLUSIONS. A history of BCG vaccination was associated with a decrease in the seroprevalence of anti–SARS-CoV-2 IgG and a lower number of participants who self-reported experiencing COVID-19–related clinical symptoms in this cohort of HCWs. Therefore, large randomized, prospective clinical trials of BCG vaccination are urgently needed to confirm whether BCG vaccination can confer a protective effect against SARS-CoV-2 infection.